Inventiva

Inventiva est une entreprise française biopharmaceutique dont le siège se situe à Daix. Elle développe deux candidats médicaments, lanifibranor et odiparcil, ainsi qu'un portefeuille de plusieurs programmes en stade préclinique.

Filings

181 filings

All Inside information100 Threshold crossing61 Earnings release13 Half-year financial report3 Universal registration document2 Quarterly financial information2

28/11/2025
Franchissement de seuils
Threshold crossingFrench
28/11/2025
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Inside informationFR
24/11/2025
Information relating to the stabilization activities carried out in the context of its recent offering
Inside information
21/11/2025
Inventiva reports 2025 Third Quarter Financial Information¹
Inside informationFR
21/11/2025
Franchissement de seuil
Threshold crossingFrench
21/11/2025
Franchissement de seuils
Threshold crossingFrench
21/11/2025
Franchissement de seuil
Threshold crossingFrench
21/11/2025
Franchissement de seuils
Threshold crossingFrench
17/11/2025
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Inside informationFR
13/11/2025
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Inside informationFR
13/11/2025
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Inside informationFR
13/11/2025
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Inside informationFR
12/11/2025
Inventiva announces launch of public offering
Inside informationFR
06/11/2025
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Inside information
06/11/2025
Information relative au nombre total de droits de vote et d’actions composant le capital social au 20 octobre 2025
Inside informationFrench
06/11/2025
Assemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
Inside informationFrench
06/11/2025
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
Inside information
14/10/2025
Inventiva Announces the Implementation of a New ATM Program
Inside informationFR
07/10/2025
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Inside informationFR
01/10/2025
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Inside informationFR
29/09/2025
RFS
Half-year financial reportFrench
29/09/2025
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Half-year financial reportFR
24/09/2025
Inventiva to Host Analyst and Investor Event on October 8, 2025
Inside informationFR
08/09/2025
Franchissement de seuils
Threshold crossingFrench
04/09/2025
Inventiva to Participate in Upcoming September Investor Conferences
Inside informationFR
25/08/2025
Franchissement de seuil
Threshold crossingFrench
25/08/2025
Franchissement de seuil
Threshold crossingFrench
19/08/2025
Franchissement de seuil
Threshold crossingFrench
19/08/2025
Franchissement de seuil
Threshold crossingFrench
19/08/2025
Franchissement de seuil
Threshold crossingFrench
12/08/2025
Franchissement de seuil
Threshold crossingFrench
12/08/2025
Franchissements de seuil
Threshold crossingFrench
11/08/2025
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Inside informationFR
11/08/2025
Franchissement de seuil
Threshold crossingFrench
11/08/2025
Franchissement de seuil
Threshold crossingFrench
11/08/2025
Franchissement de seuils
Threshold crossingFrench
31/07/2025
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inside informationFR
29/07/2025
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Inside informationFR
09/07/2025
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Inside informationFR
07/07/2025
Inventiva receives $10 million milestone payment from CTTQ
Inside informationFR
02/07/2025
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Inside informationFR
17/06/2025
Franchissement de seuils
Threshold crossingFrench
10/06/2025
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Inside information
27/05/2025
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Inside informationFR
23/05/2025
Inventiva reports 2025 First Quarter Financial Information¹
Quarterly financial informationFR
23/05/2025
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Inside informationFR
22/05/2025
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Inside informationFR
16/05/2025
Franchissement de seuil
Threshold crossingFrench
15/05/2025
Franchissements de seuils
Threshold crossingFrench
15/05/2025
Franchissement de seuil et déclaration d'intention
Threshold crossingFrench
13/05/2025
Franchissement de seuils
Threshold crossingFrench
13/05/2025
Franchissement de seuil
Threshold crossingFrench
05/05/2025
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Inside informationFR
30/04/2025
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Inside informationFR
30/04/2025
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Inside information

About

ISIN: FR0013233012
Ticker: IVA
LEI: 969500I9Y690B3FZW590
Sector: Health care
Country of registration: FR
Last filing: 30/07/2026, 22:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive